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Purpose. Somemicrobiota patterns have been associated with favorable IVF prognosis and others with pathological conditions. The
endometrial fluid aspirate (EFA) contains antibacterial proteins that are enriched in implantative IVF cycles, but the antimicrobial
effect of EFA has not been addressed. We aimed to evaluate the antimicrobial activity of the human endometrial fluid during the
natural cycle.Methods. EFA was obtained through an embryo transfer catheter in 38 women, aged 18-40 years, with regular cycles
attending to a fertility clinic. The antimicrobial activity of EFAs was tested against two strains of Staphylococcus aureus; one strain
each of Streptococcus agalactiae, Enterococcus faecalis, Escherichia coli, and Klebsiella pneumoniae; and three yeasts (Candida
albicans, Candida glabrata, and Candida krusei). Results. All samples exhibited antibacterial activity against S. aureus. In
addition, 32.4% of EFAs were active against one of the other microorganisms assayed, 16.2% against two, and 5.4% against four
of them. In contrast, none exhibited antibacterial activity against E. coli or K. pneumoniae. The antimicrobial activity differs
considerably between EFA samples, and we failed to observe a cycle-related pattern. Conclusions. EFA presented two
antimicrobial activity patterns: (a) one common to all the samples, exhibiting activity against S. aureus and lack of activity
against E. coli and K. pneumoniae, and (b) an individualized pattern, showing activity against some of the other microorganisms
tested. The intensity of antibacterial activity differs between EFA samples. Our data suggest that the uterine microbiota is
controlled by means of endometrial fluid components.
1. Introduction
Embryo implantation is one of the most inefficient steps of
assisted reproduction [1]. Implantation rates are usually
<70% even if euploid embryos are transferred [2]. Given this,
there is a growing interest in investigating the uterine role in
implantation. Since the early works of Noyes et al. [3], it is
well known that the endometrium undergoes histological
changes which are pivotal for embryo implantation.
In recent years, a huge number of different microorgan-
isms have been reported in different organs, such as the gut,
skin, lungs [4], urinary bladder [5], and vagina [6]. Some
reports have focused on endometrial microbiota. It has been
reported that endometrial and vaginal microbiota can differ
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in structure and composition [7, 8]. Indeed, a microbiota pat-
tern favorable for embryo implantation in in vitro fertiliza-
tion (IVF) cycles has been described [8].
Moreover, the secretions of cultured human endometrial
cells have shown antimicrobial activity [9–11], and antimi-
crobial peptides have been reported in them [12–14]. Never-
theless, the in vivo implication of this activity remains
unknown.
We have previously shown that endometrial fluid can be
easily aspirated [15] without impairing pregnancy rates, even
if performed at the same time as embryo transfer [16].
Depending on the analytical approach and the applied cri-
teria, somewhat more than 800 [17] or even over 2,200 pro-
teins have been detected in the endometrial fluid aspirate
(EFA) and some endogenous peptides of the EFA have
shown antibacterial activity [18]. On the other hand, we have
shown that in IVF the concentration of antibacterial peptides
in the EFA is higher in cycles where implantation occurs than
those where implantation fails [19].
However, actual antibacterial activity would presumably
be the result of interaction between different antibacterial
proteins with endogenous peptides or even with other mole-
cules present in the endometrial fluid. Thus, we have sought
to analyze the overall antibacterial activity of the EFA
obtained during natural ovarian cycles.
2. Material and Methods
2.1. Population. The population under study consisted of 38
women of Caucasian ethnicity attending the Assisted Repro-
duction Unit from the Cruces University Hospital. The inclu-
sion criteria were as follows: (i) age between 18 and 40 years;
(ii) normal uterine ultrasound; (iii) cycle length of 28-30
days; (iv) previous normal cervical cytology; (v) absence of
tubal conditions; (vi) no history of cervical infections, sexu-
ally transmitted diseases, pelvic inflammatory disease, endo-
metriosis, or polycystic ovarian disease; vii) no previous
miscarriages; (viii) 0-2 previous IVF cycles; (ix) no antibiotic
or hormonal therapy in the last 4 months; (x) normal ovarian
reserve; (xi) day of endometrial cycle 5-28; and (xii) body
mass index ðBMIÞ < 30 kg/m2.
Patients characteristics were as follows: mean age of
35:4 ± 3:8 years, duration of infertility of 2:4 ± 1:7 years,
BMI of 26:9 ± 3:8 kg/m2, 94.4% having no previous children,
66.7% having no previous IVF cycles, and 22.2% smokers. In
42% of cases, the indication for IVF was the male factor.
The study was approved by our Institutional Ethical and
Investigation Board (CEIC code 11/45).
2.2. Endometrial Fluid Collection. Patients were asked to par-
ticipate in the study by donating an EFA sample during the
mock embryo transfer, which is usually performed as a part
of the pre-IVF protocol. Written informed consent was
obtained.
A sterile disposable vaginal speculum was placed without
employing vaginal lubricants. In cases where leucorrhea pre-
cluded access to the cervical external os, the discharge was
gently removed with a sterile gauze. The EFA collection
method has been recently reported [16, 19]. An “embryo
transfer” catheter (Frydman catheter, Instrumentos Médicos
Estériles, SA, Spain) was inserted through the cervical canal,
in aseptic conditions, without it touching the vaginal walls
or the ectocervix. Abdominal ultrasound guidance was used
in order to facilitate the passing through the cervix [1] and
to prevent the catheter from touching the uterine fundus.
The sample was aspirated with gentle negative pressure
applied with a 10mL syringe connected to the catheter and
50-200μL of EFA were obtained [16, 19]. To prevent con-
tamination with cervical fluid, aspiration was interrupted at
the internal cervical os, and special care was taken to avoid
traumatizing the uterine fundus or the cervix and contami-
nating the EFA sample with endometrial tissue or blood.
Heavily blood-stained samples were discarded.
Since there is not a standardized technique to obtain EFA
for antibacterial activity analysis, we used two methods. Dur-
ing the first part of the study, the samples (n = 20; EF-01 to
EF-19 and EF-26) were expelled into standard cryogenic
tubes, and the catheter tip was cut and placed into the same
tube. In the second part of the study, after the expulsion of
EFA, the inside of the catheter was rinsed with 1mL of sterile
saline solution. The samples were immediately frozen at
−80°C until processed. Prior to be processed in the labora-
tory, the samples of the first group were filled up to 1mL final
volume with sterile saline and the catheter tip was removed
after vortexing for 15 seconds. The first method carried the
risk of dragging some germs from the cervical canal that
could produce some antimicrobial substances. In the second
case, the interior washing of the catheter would avoid this
potential contamination of the sample.
EFA samples were not collected by both methods in the
same patient because EFA is very scarce and there was a risk
that the manipulations of obtaining the first sample would
affect the quality of the second one.
2.3. Assessment of Microbial Growth from EFA Samples and
Identification of Isolates. Ten μL of each diluted sample, from
both the “cut tip” sample group and the “flushed out catheter”
group, was inoculated onto Columbia agar supplemented
with 5% sheep blood (BD, USA) and incubated at 36 ± 1°C.
Another 10μL aliquot of each sample was inoculated onto
Man, Rogosa, and Sharpe agar (MRS; Sigma-Aldrich, USA)
and incubated at 36 ± 1°C in a 5% CO2 atmosphere.
Bacterial DNA from the most frequent colony types iso-
lated from samples was subjected to PCR amplification of
the 16S rRNA gene using the bacterial universal primers
27F and 1522R as described by Kang et al. [20]. The amplicon
sequences were compared with those stored in the NCBI
database to identify the isolated bacteria.
2.4. Antimicrobial Activity of EFA Samples: Broth
Microdilution Assay. EFA samples were gently homogenized
in a rotating wheel for 30min at 4°C and then centrifuged at
2,500 g for 15 minutes to eliminate the cellular debris.
The clarified EFA samples were assayed against three
Candida strains (Candida albicans SC 5314, Candida glab-
rata ATCC 90030, and Candida krusei ATCC 6258) and six
bacterial strains (Escherichia coli CECT 434, Klebsiella pneu-
moniae CECT 144, Streptococcus agalactiae CECT 183T, and
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Enterococcus faecalis CECT 481 and two Staphylococcus
aureus strains—the CECT 435 reference strain and a
methicillin-resistant clinical isolate). ATCC stands for Amer-
ican Type Culture Collection (Manassas, VA, USA) and
CECT for Colección Española de Cultivos Tipo (Paterna,
Valencia, Spain). Candida spp. were routinely grown for
maintenance in Sabouraud agar (BD) at 36 ± 1°C for 24h,
while bacteria were grown in Nutrient Agar (Sigma-Aldrich)
under the same conditions.
The antimicrobial activity of EFA was estimated in 96-
well plates, following the guidelines of the Clinical and Labo-
ratory Standards Institute (CLSI) protocols M-27-A3 for
yeasts [21], and M07-A9 for bacteria [22], adapted to our
conditions. Briefly, Candida strains were inoculated in 100
μL of RPMI-MOPS, while bacteria were grown in Mueller-
Hinton broth. Each well was supplemented with 25μL of
the corresponding clarified EFA sample. Plates also included
a positive growth control for each microorganism (with no
EFA sample) and a negative culture medium control (no
EFA sample and no microorganism), as well as growth con-
trols for EFA samples with no added microorganisms. The
plates were incubated at 36 ± 1°C, and growth inhibition with
reference to the corresponding growth positive controls was
assessed visually at 24 h (48 h for S. aureus) using the follow-
ing scale: -, no inhibition; +, slight inhibition (less than 50%
reduction of the cell pellet in the well); ++, moderate to high
inhibition (≥50%); and +++, full growth inhibition. Growth
was always blindly assessed by the same investigator (MB-V).
2.5. Statistical Analysis. The statistical association of categor-
ical variables was analyzed with the chi-square or the Fisher’s
exact test, and P values < 0.05 were considered statistically
significant (IBM® SPSS® Statistics v.24).
3. Results
3.1. Distribution of EFA Sampling over the Menstrual Cycle.
Most EFA samples (28/38) were collected in the middle of
the cycle between days 13 and 19 (EF-12, sampled on day
16, was excluded from the subsequent study of antimicrobial
activity), while only five were collected between days 5 and 12
and another five in the late luteal phase, between days 24 and
28 (Table 1).
Twenty samples included the tip of the catheter, whereas
the remaining 18 endometrial fluids were flushed out from
the catheter. In both cases, EFA samples were made up to 1
mL final volume with sterile saline before being processed
in the laboratory.
3.2. Microbial Growth of EFA Samples. Around 50% of the
EFA samples showed no microbial growth on Columbia agar
(17/38) or MRS agar (21/38) (Table 2). The proportion of
cases with microbiological growth was significantly higher
for EFA samples stored with the catheter tip compared with
those which were flushed out (80% vs. 27.8% on Columbia
agar (χ2 = 8:44; p < 0:05) and 60% vs. 27.8% on MRS agar
(χ2 = 3:98; p < 0:05)). The analysis of the 16S rRNA gene
sequences of colonies grown from 15 EFA samples showed
that the most abundant and frequently isolated microbes
were Gram-positive rod-shaped bacteria (Lactobacillus spp.,
mostly Lactobacillus gasseri), followed by colonies of Gram-
positive coagulase-negative staphylococci (Staphylococcus
epidermidis) in five samples (EF-04, 06, 10, 12, and 26). In
contrast, other colonies from EF-02, 10, and 30 that only
grew on Columbia agar were identified as Actinomyces uro-
genitalis and Corynebacterium spp.
The frequency of positive microbial growth was 2-3 times
higher for samples that had retained the catheter tip than for
those that only contained the internal washing fluid of the
catheter. In addition, the inoculum from three out of the five
fluids with no catheter but positive growth on MRS agar only
yielded 1-2 colonies. In contrast, one of the samples that
included the catheter (EF-12, collected on day 16 of the men-
strual cycle) yielded uncountable colonies; since excessive
microorganisms interfered with the antimicrobial activity
assays, this sample was discarded for further analyses.
3.3. Antimicrobial Activity of EFA Samples. The data of anti-
microbial activity displayed in Table 1 are summarized in
Figure 1. Almost all the EFA samples studied (34/37;
91.9%) inhibited the growth of the two S. aureus strains
tested, while the remaining three samples only inhibited
one of them; none of the EFA samples exhibited full growth
inhibition of S. aureus (Table 1). In addition to inhibiting S.
aureus, 32.4% (12/37) of samples were active against only
one of the other microorganisms tested, 16.2% (6/37) against
two microorganisms, and 5.4% (2/37) against four microor-
ganisms (Table 1).
Overall, 40.5% (15/37) of EFA samples reduced the
growth of at least one of the three species of Candida, and five
of them achieved full growth inhibition against them. Some
other EFAs were active against S. agalactiae (13.5%) or E. fae-
calis (13.5%). In contrast, none of the diluted EFAs showed
activity against E. coli or K. pneumoniae (Table 1; Figure 1).
Regarding the day of EFA collection during the men-
strual cycle, all samples exhibited a certain degree of activity
against S. aureus independently of the day of collection
(Table 1). Four out of five samples that reduced the growth
of E. faecalis were obtained in the central period of the cycle
(days 14-17) and the fifth one on day 25 (Table 1). While C.
glabrata and/or C. krusei were inhibited by several fluids col-
lected at different points during the cycle (Table 1), C. albi-
cans was inhibited only by four EFA samples from days 13
and 14; thus, the activity against C. albicans was statistically
associated (p < 0:05) with EFA samples from the first part
of the cycle (days 1-14) compared to the second part (days
14-28). Three EFA samples—EF04, EF06, and EF26—were
active against two species of Candida (C. glabrata and C. kru-
sei) and two—EF01 and EF27—against all three species
tested (C. albicans, C. glabrata, and C. krusei).
Although care was taken to avoid epithelial bleeding dur-
ing the sample collection, antibacterial activity against S. aga-
lactiae was only registered in five out of 20 samples that
contained traces of blood (EF-01, 05, 11, 14, and 25; Table 1).
As for the antimicrobial activity of EFA depending on the
presence of culturable microorganisms in the samples, we
found no differences in anti-S. aureus activity: all samples
inhibited the growth of at least one of the two strains tested
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(Table 1). However, antimicrobial activity against the rest of
microorganisms tested was somewhat more frequent in cases
where the microbial culture of EFA on MRS and/or Colum-
bia agar was positive (15/23; 65.22%) than those with no
culturable bacteria (5/14; 35.71%) (χ2 = 3:05; p = 0:08)
(Table 1). In regard to the collection method and storage,
Table 1: Time distribution, sample characteristics and antimicrobial activity of EFA samples.
Cycle
day























5 EF-05 Yes Yes - - - + - + - - +
10
EF-07 Yes Yes - - - - ++ ++ - - -
EF-22 No No - - - - + + - - -
11 EF-24 No Yes - - - - + - - - +++
12 EF-23 No No - - - - + ++ - - -
13
EF-01 Yes Yes - - - ++ ++ ++ +++ +++ +++
EF-02 Yes Yes - - - - + ++ - - -
EF-10 Yes Yes - - - - ++ + - ++ -
EF-28 No No - - - - - + ++ - -
EF-29 No No - - - - ++ + - - -
14
EF-15 Yes Yes - - - - + + - - -
EF-20 No No - - - - ++ + - - -
EF-21 No Yes - - - - + ++ +++ - -
EF-25 No No - - - + ++ ++ - - -
EF-27 No No - - + - + ++ +++ +++ +++
15
EF-04 Yes Yes - - - - + ++ - ++ +
EF-19 Yes Yes - - - - + + - ++ -
EF-30 No Yes - - - - ++ ++ - - -
EF-37 No No - - - - ++ + - - -
16
EF-03 Yes Yes - - - - + ++ - - +
EF-13 Yes Yes - - + - + + - - -
EF-16 Yes No - - + - ++ ++ - - -
EF-26 Yes Yes - - - - + ++ - + ++
EF-31 No Yes - - - - ++ + - - -
EF-35 No Yes - - - - ++ ++ - - -
EF-36 No Yes - - - - ++ ++ - - -
17
EF-33 No No - - + - ++ + - - -
EF-34 No No - - - - + + - - -
18
EF-06 Yes Yes - - - - + + - +++ +
EF-14 Yes Yes - - - +++ + + - - -
19
EF-18 Yes Yes - - - - + + - - -
EF-32 No No - - - - + + - - -
24 EF-17 Yes No - - - - + + - - -
25 EF-11 Yes Yes - - - + ++ ++ - ++ -
26 EF-08 Yes Yes - - - - + ++ - - +
27 EF-09 Yes Yes - - + - ++ + - ++ -
28 EF-38 No No - - - - ++ + - - -
aAntimicrobial activity with reference to the cell pellet of the positive growth control well. -: no inhibition; +: slight inhibition (<50% reduction); ++: moderate to
high inhibition (≥50%); +++: full growth inhibition. bCatheter: “yes” stands for samples stored with the catheter tip prior to processing; “no” stands for samples
flushed out from the catheter before being stored. Microorganisms: Escherichia coli, Klebsiella pneumoniae, Enterococcus faecalis, Streptococcus agalactiae,
Staphylococcus aureus, MRSA (Methicillin-resistant S. aureus), Candida albicans, Candida glabrata, and Candida krusei.
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samples that included the catheter tip were more frequently
associated with activity against microorganisms other than
S. aureus (14/19; 73.68%) than those that contained only
the flushing fluid from inside the catheter (6/18; 33.33%),
and this association was statistically significant (χ2 = 6:06;
p < 0:05).
4. Discussion
Microbial populations of varied composition have been
described in association with different anatomical locations
of the human body [23]. The interaction between the host
and microbiota has been shown to play an essential role in
many aspects of human physiology [24–26].
Much less is known about the uterine side of implanta-
tion than the embryonic side. The challenges of investigating
the uterine side of implantation include endometrial cyclic
changes, intercycle variability, and the influence of ovarian
stimulation on endometrial changes, as well as the potential
adverse effect of endometrial biopsy on implantation, if per-
formed close to the time of embryo transfer [16]. In this con-
text, we have focused our study on EFA, which can be
obtained at the same time as embryo transfer, without
impairing implantation rates [16].
Moreno et al. [8] identified a favorable pattern in the
endometrial microbiota for the successful implantation of
the embryo in IVF, characterized by a high proportion of
Lactobacillus. In a recent study focusing on the protein com-
position of EFA obtained at the same time as the embryo
transfer, we showed that EFA from IVF cycles where implan-
tation took place (“implantative” cycles) was richer in anti-
bacterial proteins than EFA from “nonimplantative” cycles
[19]. This is in agreement with very recent data from an
endogenous peptidomics-focused mass spectrometry analy-
sis of EFA describing the presence of a number of peptides
with potential antibacterial activity in this fluid [18]. In line
with this, selected in silico predicted antibacterial peptides
were synthesized and tested in vitro for antimicrobial activ-
ity. Preliminary results showed that, indeed, some of these
peptides present antibacterial activity [18]. In the same way,
it has recently been suggested that the innate immune system
senses pathogen-associated molecular patterns and this could
induce the release of antimicrobial peptides into the uterine
cavity [27].
In the present study, we have evaluated the antimicrobial
activity of EFA, which contains many different antibacterial
proteins and peptides, whose synergisms or even antago-
nisms are still unknown. Indeed, some microorganisms pres-
ent in EFA could also play an antibacterial role. For instance,
the Lactobacillus genus produces lactic acid and short-chain
fatty acids, acidifying the environment to pH ≤4.5 in the
vagina and prohibiting the growth of other pathogenic or
dysbiotic bacteria in healthy women [28, 29]. However, con-
cerning the endometrium, no correlation has been observed
between the pH value and the endometrial microbiota [8].
The possibility of sample contamination is a significant
hurdle to investigate uterine microbiota [30]. There is no
standardized methodology for the study of human uterine
microbiota [30]. In most of the studies, the samples were col-
lected through the cervix [30]. Some authors used endome-
trial biopsies [31], others used transcervical aspiration
through an embryo transfer catheter [8, 32–34] and then
emptied the content (without flushing out the catheter),
others used a double lumen catheter, without aspiration,
and analyzed the distal portion of the transfer catheter [7,
35], and some combined a double lumen ET catheter with
lavage and endometrial biopsy [36]. Aspiration of EF under
aseptic conditions has been shown to be a safe and effective
Table 2: Microbial growth of endometrial fluid aspirate (EFA) samples from 38 women on Columbia agar and MRS agar. The ratio of EFA
samples displaying microbial growth in both media was significantly higher for those stored with the catheter tip (∗χ2 = 8:44, p < 0:05; ∗∗
χ2 = 3:98, p < 0:05) compared to EFA samples flushed out from the catheter.
Microbial growth of EFA samples on
Columbia agar MRS agar
Positive Negative Positive Negative
EFA samples N N % N % N % N %
With catheter tip 20 16 80∗ 4 20 12 60∗∗ 8 40
Flushed out from catheter 18 5 27.8 13 72.2 5 27.8 13 72.2

























































































Figure 1: Percentage of EFA samples with antimicrobial activity
against different microorganisms. Color code refers to the
intensity of inhibition as described in Material and Methods (blue:
+; yellow: ++; salmon: +++).
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method to evaluate the endometrial microbiota [8, 37]. We
have undertaken this work in order to evaluate the potential
antimicrobial activity of the endometrial fluid of 38 women
in reproductive age. The EFA samples were collected through
aspiration with an embryo transfer catheter passed through
the cervical os, taking precautions to avoid contamination
with the cervix microbiota. Two different collection methods
were used: (i) emptying the catheter content and storing the
sample with the catheter tip and (ii) flushing the inside of
the catheter with saline solution. In our work, approximately
half of the EFA samples contained culturable microorgan-
isms, in agreement with data stating that the endometrial
cavity is not sterile in most healthy women [38].
Twice as many positive cultures were obtained from sam-
ples stored with the catheter tip compared to samples without
it. Colonies of Staphylococcus epidermidis were only identi-
fied in those samples stored with the catheter. It could be
speculated that the external surface of the catheter retained
a number of microorganisms from the cervical canal, and
hence, for microbiological analyses, it seems advisable to col-
lect only the internal fluid of the catheter. Nevertheless, the
viable bacteria identified in both sample types consisted
mainly of Lactobacillus spp. and to a much lesser extent Acti-
nomyces urogenitalis and Corynebacterium spp. Lactobacillus
spp. were the most frequently isolated bacteria from the EFA
samples, in agreement with previous reports of Wee et al.
[39] and Moreno and Simon [37]. Although significant dif-
ferences have been reported in vaginal and uterine microbi-
ota [8, 33, 34, 40], as far as we know, cervical and uterine
microbiota have not been compared. Selman et al. studied
endocervical and ectocervical samples as well as the internal
tip of the catheter, but they did not aspirate samples and
the results for each localization were not compared [35].
There is also a controversy about the method of analysis
of the uterine microbiome. Regarding the culture of viable
microbes, less than 1% of the bacteria present in a sample
grow and form colonies; furthermore, some human samples
may contain a limited amount of microorganisms [41]. On
the other hand, the next-generation sequencing (NGS)
analysis of EFA samples containing a small number of
microorganisms may be distorted by abundant contaminat-
ing vaginal microbiota [30]. Moreover, NGS readings do
not differentiate between live and dead microorganisms,
and consequently, the uterine microbial population may
be overestimated.
The uterine microbiota have been reported to fluctuate
with menstrual cycle timing [42], ovarian stimulation [43],
ethnic group [44], certain pathological conditions [42], and
IVF prognosis [37]. In our study, performed in natural cycles
of Caucasian women in reproductive age, we have not been
able to establish a clear association between the viable micro-
biota of EFA samples and the time of sampling during the
menstrual cycle. However, we acknowledge that only a small
number of the samples studied were outside the central part
of the cycle.
Regarding the antimicrobial activity, all the EFA samples
in the present work inhibited the in vitro growth of S. aureus
to some extent, and there were no significant differences
between culturable and nonculturable samples, or even
between samples collected at different times over the men-
strual cycle. A number of potential antibacterial peptides
have been reported from human endometrial tissue cultures
[12–14]. Our results are consistent with those obtained with
cultures of uterine epithelial cells [45], showing the produc-
tion of antibacterial factors that effectively killed S. aureus,
and correlation with secretory leukocyte protease inhibitor
concentrations. Nevertheless, in the same study on uterine
epithelial cell culture [45], antibacterial activity against E. coli
was also observed, a type of activity that was not observed in
any patients from our study. We were also unable to find any
activity against K. pneumoniae in any of our patients’ EFA
samples. On the other hand, more than half of the EFA sam-
ples of the studied women (54.1%) exhibited antimicrobial
activity against other microorganisms including C. albicans,
C. glabrata, C. krusei, S. agalactiae, and/or E. faecalis. More-
over, our findings regarding C. albicans are in agreement
with those of Wira et al. [46], who reported that secretions
of cultures from the upper female reproductive tract cells
inhibit yeast and hyphal forms of C. albicans.
It has to be stressed that there was a remarkable heteroge-
neity in antimicrobial activity patterns: (i) the intensity of the
antimicrobial activity differs notably between the different
specimens, and (ii) apart from S. aureus which was always
inhibited, the proportion of EFA inhibiting some of the
remaining microorganisms assayed ranged from 10.8 to
24.3%. Furthermore, in addition to S. aureus, 32.4% of
EFA samples were active against only one of the remaining
microorganisms assayed, 16.2% against two microorgan-
isms, and only 5.4% against four microorganisms. On the
other hand, it must be highlighted that a number of micro-
organisms, especially anaerobic bacteria, were not evaluated
in our study.
Concerning the source of antibacterial compounds, in
addition to endometrial tissue, as suggested by tissue culture
studies, one cannot rule out an associated effect coming from
the microbiota of the endometrial cavity. In agreement with
this, apart from the anti-S. aureus activity which was present
in every sample, we found that antimicrobial activity against
the other tested microorganisms was more frequent in the
samples where microbiological cultures were positive. Wang
et al. [47] attributed antimicrobial activity to Lactobacillus
spp. that produces lactic acid and hydrogen peroxide, among
other compounds, which can inhibit the growth of poten-
tially pathogenic bacteria, as well as the filamentation of C.
albicans. Nonetheless, the anaerobic environment of the
endometrium does not facilitate hydrogen peroxide produc-
tion by Lactobacillus. Indeed, we have documented anti-Can-
dida activity in more than one-third of the EFA samples,
even in cases when no growth of Lactobacillus on MRS
medium was recorded. Regarding the method of collec-
tion and storage, the samples containing only the fluid
flushed out from the catheter were associated with the
least frequently positive cultures and antimicrobial activity.
Although our sample numbers were limited and we were
unable to assess a range of confounding factors, the latter
method is probably the one that can provide the most reliable
information on the uterine microbiota and its antimicrobial
activity.
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In this study, we have shown that EFA samples from
women of reproductive age exhibit antimicrobial activity
against some microorganisms that could impair IVF results.
All the EFA samples tested in vitro reduced the growth of
S. aureus, and many of them inhibited Candida spp., E. faeca-
lis, and/or S. agalactiae as well, but not E. coli or K. pneumo-
niae. To the best of our knowledge, this is the first report on
the direct antimicrobial activity of endometrial fluid aspirate
samples in humans.
Further studies are warranted to characterize the endo-
metrial fluid of women undergoing IVF procedures in order
to assess whether there is a relationship between the antimi-
crobial activity of raw EFA and implantation success.
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